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Abstract 
Background: Acute myocardial infarction (AMI) might lead to left ventricular remodeling. Adequate 
myocardial perfusion is critical to prevent this adverse remodeling. Quantitative myocardial blush 
evaluator (QuBE) software, available on-line, is a simple analysis tool which enables  the precise quan-
tification of myocardial perfusion in the infarct area immediately after interventional treatment. The 
aim of this study was to assess whether the results of QuBE analysis might predict the development of 
heart failure (HF) in AMI patients in 3 year-long follow-up.  
Methods: Ninety five patients with first AMI, single vessel coronary artery disease, Killip class I at 
presentation were enrolled in the study. Angiograms were reanalyzed using the on-line QuBE software. 
Data on heart failure development (ICD 10 codes I50) provided by the National Health Fund were 
considered as primary outcome. 
Results: QuBE values ranged from 0.0 to 25.3 arbitrary units, mean value was 9.9 ± 5.2 arbitrary 
units. QuBE correlated positively with myocardial blush grade (MBG; Spearman R = 0.342 at p < 0.05).  
Multivariate Cox proportional hazard modeling, adjusted for initial Thrombolysis in Myocardial In-
farction (TIMI flow, and TIMI thrombus grade indicated QuBE score (1 unit increase — HR 0.919, 
95% CI 0.846–0.999, p = 0.049) and left ventricular ejection fraction at discharge (1% increase — HR 
0.936, 95% CI 0.902–0.971, p = 0.000) as independent predictors of HF development.  
Conclusions: The QuBE assessment of myocardial perfusion allows the prediction of HF development 
in the post-infarction period in this highly selective group of patients. (Cardiol J 2019; 26, 4: 322–332)
Key words: acute myocardial infarction, left ventricular remodeling, primary  
percutaneous coronary intervention, quantitative myocardial blush evaluator 
Introduction
The advent of interventional treatments for 
acute myocardial infarction (AMI) has greatly 
improved patient survival. Despite continuous 
progress in interventional tools and techniques, 
immediate results of primary coronary angioplasty 
remain far from optimal. Up to 40% of patients with 
restored normal epicardial blood flow Thrombolysis 
in Myocardial Infarction (TIMI) III has impaired 
myocardial perfusion [1] and microvascular ob-
struction arises as a major obstacle in complete 
heart muscle recovery [2, 3]. Coronary microvas-
cular dysfunction is responsible for infarct expan-
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sion and adverse remodeling of the left ventricle 
(LV) [4] and might eventually result in overt heart 
failure (HF) [5]. 
Myocardial blush grade (MBG), an angio-
graphic measure of myocardial perfusion, was 
proven to correlate with enzymatic infarct size, 
echocardiographically assessed left ventricular 
ejection fraction (LVEF) [6], mortality [6, 7], and 
higher incidence of LV remodeling [1]. Moreover, 
authors of the latter paper [1], have reported almost 
60% incidence of signs and symptoms of congestive 
HF within 6 months after AMI in patients in whom 
myocardial perfusion was inadequate (MBG 0 and 
1) after primary coronary angioplasty. There are 
also contradictory data and several small studies 
have reported the lack of correlation between MBG 
and myocardial perfusion assessed by contrast 
echocardiography [8, 9]. Furthermore, Bertomeu-
-Gonzalez et al. [10] have raised the question on 
inter-observer variability of MBG assessment, 
have reported on a lack of correlation between 
MBG and LVEF assessed with magnetic resonance 
imaging (MRI). Authors of additional studies point 
out superior performance of TIMI myocardial 
perfusion scale (TMP) over MBG in correlation 
with other indices of myocardial perfusion [1, 11].
Reference diagnostic methods of perfusion 
assessment, such as the evaluation of the coronary 
blood flow velocity [12, 13], myocardial contrast 
echocardiography [14, 15], or MRI [16, 17], are 
not widely used for prognostic purposes in post-
infarction patients. 
A simple, robust, free of operator bias method 
of myocardial perfusion assessment with an abil-
ity to stratify patient risk would be invaluable in 
clinical practice. The quantitative myocardial blush 
evaluator (QuBE) software appears to be encour-
aging in this regard [18]. The QuBE was designed 
to facilitate an operator-independent assessment 
of myocardial perfusion. It correlates with other 
measures of infarct size and myocardial perfusion 
[18, 19]. Higher QuBE values indicate at improved 
survival [18] and better LV performance [20]. 
The aim of this proof-of-concept study was 
to assess whether the results of a QuBE analysis 
might be useful to predict HF development in 
stable, post-infarction patients who had survived 
their first myocardial infarction (MI). 
Methods 
Study population
This study is a  retrospective review of medi-
cal records of patients admitted with ST-segment 
elevation myocardial infarction (STEMI) between 
January 2004 and December 2014. Diagnosis of 
STEMI was based on chest pain lasting more than 
20 min, ST-segment elevation in electrocardiog-
raphy, or positive findings for myocardial necrosis 
markers. Out of 1469 consecutive patients, 696 
patients had incomplete medical records, different 
myocardial necrotic markers, faded or unreadable 
electrocardiogram (ECG) tracings, 543 had poor 
quality of angiograms with short contrast injections 
and recordings, or with overlapping distal parts of 
vessels. Out of 230 patients with complete medical 
data, 95 patients have met inclusion criteria into 
this single center study (first MI, no evidence of 
HF at admission or prior to admission, single ves-
sel disease, and major coronary artery LAD, Cx, 
RCA as infarct-related vessel) and were selected 
for further analysis with 36 month-long follow-up 
(Fig. 1). All patients had been treated with primary 
percutaneous angioplasty. The administration of 
glycoprotein (GP) IIb/IIIa inhibitors as well as the 
use of aspiration catheters was at the operator’s 
discretion. Demographic, clinical, procedural, and 
laboratory data were recorded. 
Angiographic assessment 
Archived angiographic DICOM records were 
reanalyzed by a single reviewer (AT). For inter-
observer analyses another observer (MO) was 
Figure 1. Flow chart of patients with ST-segment eleva-
tion myocardial infarction (STEMI) treated from 2004 
to 2014; CABG — coronary artery bypass grafting; 
PCI — percutaneous coronary intervention.
1469 STEMI patients treated 2004–2014
696 patients with incomplete 
medical records
543 patients with inadequate 
angiogram quality
230 patients with QuBE score assessed
95 patients eligible for analysis with 36 months follow-up available
135 patients with exclusion criteria:
Previous myocardial infarction
Patients with multivessel disease 
scheduled for further PCI or CABG
Patients in Killip II–IV class
773 patients with angiographic records reviewed
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asked to review randomly selected angiograms. 
Both reviewers were blinded to QuBE score re-
sults. The original operator descriptions of the 
primary percutaneous procedures, which were 
lacking initial or final TIMI flow values and MBGs, 
were recorded by the reviewer. For thrombus clas-
sification a score proposed by Gibson et al. [21] 
was used. In patients presenting with an occluded 
infarct-related artery (IRA) (grade 5 thrombus, es-
sentially no flow), thrombus was reclassified into 
one of the other categories after flow achievement 
with either guide-wire crossing or a small (diam-
eter 1.5 mm) deflated balloon passage or dilation 
[22]. A corrected TIMI frame count was calculated 
for the IRA in the final angiogram according to 
Gibson et al. [23]. MBG was evaluated according 
to van’t Hof et al. [6] and was judged in the final 
angiogram. For the operator-independent evalua-
tion of myocardial perfusion, an on-line software 
was used. (Quantitative Blush Evaluator available 
at http://www.stellarjackpot.com/qube/ recently 
[18]). For detailed intra- and inter-observer vari-
ability assessment of myocardial perfusion see 
Supplementary material on-line. 
Non-invasive reperfusion, infarct-size,  
and LVEF assessment 
For a non-invasive assessment of myocardial 
perfusion,  the electrocardiographic indices of ST 
reduction according to van’t Hof et al. [24] was 
used. Electrocardiograms were reviewed by TM, 
EN, KP, and AI. For assessment of infarct size, 
peak activity of creatine kinase and troponin 
T concentration area under the curve (AUC) 
measured at admission was utilized at 12, 24, and 
72 hours. AUC was calculated with formula: TpAUC 
= 0.5 × Tp0 + 0.5 × Abs(Tp12 – Tp0) + 0.5 
× Tp12 + 0.5 × Abs(Tp24 – Tp12) + 2 × Tp72 
+ Abs(Tp72 – Tp24), where Tp0, Tp12, Tp24, Tp72 
are respective troponin concentrations, and Abs is 
the absolute value of the subtraction. AUC was ex-
pressed in ng/L × 24 h (Suppl. material on-line). 
The pre-discharge LVEF, LV end-diastolic volume 
(LVEDV), and LV end-systolic volume (LVESV) 
from patients’ archives. LVEF was measured us-
ing biplane Simpson’s method [25] with software 
integrated in GE Vivid 7 Dimension echocardiogra-
phy machine (GE Vingmed, Horten, Norway) was 
recorded. LVEDV and LVESV were indexed for 
body surface area (BSA) and expressed as mL/m2. 
BSA from patient’s baseline height and weight ac-
cording to Mosteller’s formula [26] was calculated.
Study endpoint 
Study endpoint was the development of new 
onset HF. International Classification of Diseases, 
10th revision (ICD-10) codes I50.0–I50.9 reported 
to National Health Fund (NHF) were considered 
as HF development. The present methodological 
approach followed these steps. First the Silesian 
Division of NHF was asked to provide us with vital 
status of patients with respective dates of deaths 
and the dates when patients were registered with 
I50.0–50.9 coding numbers. The electronic data 
file from NHF included multiple entries for some 
patients with different dates of HF reported to 
NHF. Additional information was provided by the 
NHF; the general identifier of medical institution 
reporting on the patient  (internal medicine ward, 
cardiology ward). The assumption was that the ear-
liest date was the date of new onset HF. One more 
assumption was accepted: patients with coinciding 
dates of HF and death were censored in Kaplan-
-Meier analysis. Then assumptions were validated 
and cross-checked with source documentation for 
any annotation of symptoms, signs, and inotropic 
or diuretic drugs administered which included 
final diagnosis of new onset HF, and the returned 
information from NHF on the diagnosis of HF in 
the observed patients. Eight events of new onset 
HF were recorded during index hospitalization for 
STEMI treatment and 8 patients were reported 
from NHF with the ICD-10 50.0–50.9 numbers. 
Thus, 8 out 39 cases (approx. 20%) were validated. 
The date of HF occurrence was assigned as the 
admission date. An exception was made for patients 
who had revealed HF symptoms and required 
administration of diuretics, or inotropic support 
during the index hospitalization for AMI treatment. 
The date of symptom appearance and/or adminis-
tration of drugs, recorded from medical archives 
was considered as the date of HF development. 
Statistical analysis 
Quantitative data are presented as the means 
and standard deviations (or standard error of the 
mean in cases of necrotic markers) and categorical 
data are presented as numbers and percentages. 
Data were analyzed for normal distribution with 
the Kolmogorow-Smirnov test and for homogene-
ity of variances with Levene’s test. Groups were 
compared with a Student t test or c2 test with Yates 
correction. Non-parametric correlation as well 
as linear regression analysis was used to assess 
relationship of QuBE score with other variables. 
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Receiver operator characteristic (ROC) curves were 
calculated for HF development and QuBE score 
as de-stimulating factor. Different discrimination 
methods for ROC analysis were used. A tangent 
method provided QuBE score cut-off value of 
7.6 arbitrary units with specificity 0.49 and sensitivi- 
ty 0.68. The Youden method provided a QuBE score 
cut-off value of 13.3 arbitrary units with specific-
ity 0.9 and sensitivity 0.32. Both cut-off values, as 
well as QuBE score tertiles were used for Kaplan-
-Meier survival modeling. HF development in the 
follow-up was considered as complete observation, 
any death occurring before HF development was 
considered as a censored observation. Univariate 
and multivariate Cox proportional hazard modeling 
was used to find predictors of HF development. 
Differences in the means or frequencies were 
considered significant when p < 0.05. Statistica 
12 (Statsoft Inc., Tulsa, USA), equipped with the 
Medical Package (Statsoft Polska, Krakow, PL) was 
used for data analysis. 
Results 
QuBE assessment 
QuBE values ranged from 0.0 to 25.3 arbitrary 
units, mean value was 9.9 ± 5.2 arbitrary units. 
QuBE positively correlates with MBG (Spearman 
R = 0.342 at p < 0.05). Reproducibility, variabil-
ity, and agreement analyses for visual (MBG) and 
computer-assisted myocardial (QuBE) perfusion 
assessment indicate increasing diagnostic accuracy 
of the latter method. Moreover, QuBE scores cor-
relate negatively with symptom duration (p < 0.05) 
(Suppl. material on-line). 
Clinical and angiographic presentation, 
procedural outcomes 
For clarity of presentation, patients were clas-
sified and shown in tables according to clinical sta-
tus at follow-up: 56 patients without new onset HF 
(no HF) and 39 patients with new onset HF in the 
follow-up (HF). Patient demographics and myocar-
dial infarction characteristics are shown in Table 1. 
Angiographic and procedural data are presented 
in Table 2. Table 3 presents electrocardiographic 
assessment of reperfusion, enzymatic infarct size, 
LV function and volumes at discharge. While the 
groups are comparable in regard to baseline pres-
entation, they differ significantly in TIMI thrombus 
classification, QuBE score, troponin concentration, 
and pre-discharge LVEF. HF group had significantly 
higher thrombus burden after reclassification — 
19 (48.7%) patients had thrombus grade III–V as 
opposed to 15 (26.8%) patients with thrombus 
grade III–IV (none with grade V thrombus) in no 
HF group. This feature was accompanied by lower 
myocardial perfusion as assessed with QuBE score, 
higher enzymatic infarct size, and lower LVEF at 
discharge in HF group.
Table 1. Demographic and baseline presentation of patients divided into groups according to heart 
failure (HF) development.
No HF (n = 56) HF (n = 39) Statistics Significance
Men/women 41/15 23/16 c2 NS
Age [years] 61.5 ± 11.4 65.3 ± 12.3 Student’s t test NS
Hypertension 39 (69.6%) 29 (74.4%) c2 NS
Diabetes 17 (30.4%) 13 (33.3%) c2 NS
Hyperlipidemia 29 (51.8%) 21 (53.8%) c2 NS
Smoking 28 (50.0%) 21 (53.8%) c2 NS
Family history 13 (23.1%) 12 (30.8%) c2 NS
Creatinine [μmol/L] 84.2 ± 32.4 85.4 ± 31.8 Student’s t test NS
Body mass index [kg/m2] 28.0 ± 4.3 28.5 ± 4.3 Student’s t test NS
Body surface area [m2] 2.0 ± 0.2 1.9 ± 0.2 Student’s t test NS
Infarct location: 
Anterior 22 (39.3%) 19 (48.7%) c2 NS
Inferior 34 (60.7%) 20 (51.3%)
Symptom duration [min] 387.0 ± 411.0 387.2 ± 278.4 Student’s t test NS
Time door-to-needle [min] 32.5 ± 29.6 33.9 ± 32.4 Student’s t test NS
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Long-term outcome assessment 
Follow-up was terminated at 36 months. 
Events which occurred in the first 36 months were 
included in the analysis. Patients were followed 
for a median time of 428 days (interquartile range 
60–977 days, mean 528 ± 437.4 days). Patients 
at discharge from hospital were administered 
comparable medical treatment (Table 4). Accord-
ing to NHF data, during the follow-up 39 (41.1%) 
patients were reported to have developed HF. 
Table 2. Angiographic and procedural data for groups according to heart failure (HF) development.
No HF (n = 56) HF (n = 39) Statistics Significance
Infarct related artery: c2 NS
LAD 22 (39.3%) 19 (48.7%) 
Cx 6 (10.7%) 3 (7.7%) 
RCA 28 (50.0%) 17 (43.6%) 
Initial TIMI flow: c2 NS
0 25 (44.6%) 18 (46.2%)
I 2 (3.6%) 6 (15.4%)
II 7 (12.5%) 4 (10.2%) 
III 22 (39.3%) 11 (28.2%)
TIMI thrombus grade initial/reclassified: c2 p = 0.02
0 11/18 (19.6/32.2%) 3/4 (7.7/10.3%)
I 9/12 (16.0/21.5%) 9/11 (23.1/28.2%)
II 6/11 (10.7/19.6%) 3/4 (7.7/10.3%) 
III 3/6 (5.4/10.7%) 2/5 (5.1/12.8%)
IV 1/9 (1.8/16.0%) 2/11 (5.1/28.2%)
V 26/0 (46.5/0.0%) 20/4 (51.3/10.3%)
Thrombus aspiration 17 (30.4%) 11 (28.2%) c2 NS
Glycoprotein IIb/IIIa inhibitors: c2 NS
None 27 (48.2%) 20 (51.3%)
Abciximab 17 (30.4%) 16 (41.0%)
Integriline 12 (21.4%) 3 (7.7%) 
Stent implantation: c2 NS
BMS 29 (51.8%) 24 (61.5%)
DES 21 (37.5%) 9 (23.1%)
Temporary pacing 2 (3.6%) 0 (0.0%) c2 NS
Final TIMI flow: c2 NS
0 1 (1.8%) 3 (7.7%)
I 2 (3.6%) 3 (7.7%)
II 3 (5.4%) 4 (10.3%)
III 50 (89.2%) 29 (74.3%)
cTFC [Frame/s] 28.6 ± 21.2 37.4 ± 28.9 Student’s t test NS
Myocardial blush grade: c2 NS
0 3 (5.4%) 5 (12.8%)
I 4 (7.1%) 5 (12.8%)
II 16 (28.6%) 9 (23.1%)
III 33 (58.9%) 20 (51.3%)
AVDE 7 (12.5%) 6 (15.4%) c2 NS
Procedural success 40 (71.4%) 26 (66.7%) c2 NS
AVDE — angiographically visible distal embolization, BMS — bare metal stent; cTFC — corrected TIMI frame count; DES — drug eluting stent; 
LAD — left anterior descending artery; Cx – circumflex artery; QuBE – quantitative blush evaluator; RCA — right coronary artery; TIMI — 
Thrombolysis in Myocardial Infarction
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Using two different discrimination methods for ROC 
analysis  two different QuBE score cut-off values 
were received (Fig. 2). A tangent method provided 
QuBE score cut-off value of 7.6 arbitrary units with 
specificity 0.49 and sensitivity 0.68. A Youden’s 
method provided QuBE score cut-off value of 13.3 
arbitrary units with specificity 0.9 and sensitivity 
of 0.32. Both methods yield the same AUC 0.599 
at p = 0.08. Both cut-off values, as well as QuBE 
score tertiles were used for Kaplan-Meier survival 
modeling and its results are shown in Figure 3 with 
three different panels for different cut-off values. 
The QuBE score cut-off value of 13.3 arbitrary 
units provides the most significant (p = 0.01) dif-
ference between the groups in survival without HF 
development. Univariate Cox proportional hazard 
analysis has disclosed several demographic, clini-
cal, angiographic, and procedural variables as those 
related significantly to HF development (Table 5). 
Of those, initial TIMI flow and thrombus burden 
after reclassification as primary variables (i.e. vari-
ables that existed before or at the very beginning of 
Table 3. Electrocardiographic assessment of reperfusion, enzymatic infarct size and left ventricle  
function at discharge in patients divided into groups according to heart failure (HF) development.
No HF (n = 56) HF (n = 39) Statistics Significance
QuBE [arb. units] 10.8 ± 5.7 8.6 ± 4.1 Student’s t test 0.045
ST-segment elevation resolution: c2 NS
None 11 (19.6%) 13 (33.3%)
Partial 32 (57.2%) 15 (38.4%)
Complete 13 (23.2%) 11 (28.3%)
Peak CK-MB [IU/L] 194.2 ± 39.6 237.8 ± 32.1 Student’s t test NS
Troponin T [ng/L]: Student’s t test NS
Baseline 505.1 ± 92.3 842.3 ± 270.1
12 h 2751.9 ± 318.2 3590.2 ± 471.7 NS
24 h 2205.8 ± 232.5 3158.2 ± 357.4 0.022
72 h 1472.7 ± 140.9 2069.3 ± 221.9 0.019
TpT AUC [ng/L*days] 6894.7 ± 713.7 9595.8 ± 1034.8 0.029
LVEF [%] 44.0 ± 9.8 38.7 ± 11.6 Student’s t test 0.017
LVEDVI [mL/m2] 62.8 ± 13.6 60.2 ± 16.0 Student’s t test NS
LVESVI [mL/m2] 34.5 ± 6.8 35.7 ± 7.0 Student’s t test NS
CK-MB — creatine kinase muscle-brain isoenzyme; QuBE — quantitative myocardial blush evaluator; LVEF — left ventricular ejection fraction; 
LVEDVI — left ventricular end-diastolic volume index; LVESVI — left ventricular end-systolic volume index; TpT AUC — troponin T area under 
the curve 
Table 4. Medical treatment of patients at discharge depending on heart failure (HF) development in 
follow-up.
No HF (n = 56) HF (n = 39) Statistics P
Clopidogrel 56 (100.0%) 39 (100.0%) c2 NS
Beta-blockers 54 (96.4%) 38 (97.4%) c2 NS
ACEI/ARB 56 (100.0%) 39 (100.0%) c2 NS
Calcium channel antagonists  9 (16.1%) 4 (10.3%) c2 NS
Statin 54 (96.4%) 36 (92.3%) c2 NS
Oral anticoagulation 9 (16.1%) 7 (17.9%) c2 NS
Loop diuretics 10 (17.9%) 17 (43.6%) c2 NS
Spironolactone 3 (5.4%) 4 (10.3%) c2 NS
Digoxine 1 (1.8%) 1 (2.6%) c2 NS
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker
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invasive procedure) were used for stratification of 
multivariate model. Multivariate model corrected 
TIMI frame count, QuBE score, troponin T AUC, 
and the pre-discharge LVEF were introduced, 
while only QuBE score and LVEF remained  in-
dependent predictors of HF development in the 
36 month-long follow-up (Table 5). During hospital 
stay 5 patients died: 2 patients within 24 h after 
primary angioplasty, and 3 more patients died after 
they have developed HF as the direct causes of 
all death ventricular arrhythmias. In the follow-up 
7 more deaths occurred. They did not coincide with 
a new onset HF.  
Discussion
This study shows results from a quantitative 
myocardial blush evaluation assessed immediately 
after interventional treatment of STEMI allowing 
for prediction of HF development in long term 
follow-up. Nonetheless it should be underlined 
that there are some peculiar features of the study 
population.  Enrolled into this study was highly 
selective population with first time MI, who had 
been classified in Killip class I. Considering larger 
Figure 2. Receiver operator characteristic curve for 
quantitative myocardial blush evaluator (QuBE) values 
and heart failure development in 36-month-long follow-
up with two different discrimination methods: tangent 
(QuBE score = 7.6 arb. units) and Youden’s method 
(QuBE score = 13.3 arb. units); AUC — area under the 
curve.
Figure 3. Kaplan-Meier survival curves without heart failure development depending on quantitative myocardial 
blush evaluator (QuBE) score cut-off value 7.6 arbitrary units (A), 13.3 arbitrary units (B), and QuBE score tertiles (C); 
°Complete; +Censored.
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Table 5. Univariate and multivariate predictors of heart failure development in ST-segment elevation 
myocardial infarction patients in 36 months-long follow-up.
Univariate Multivariate
HR 95% CI P HR 95% CI P
Demographic and clinical 
Age (1 year increase) 1.022 0.993–1.051 0.137
Male sex 0.581 0.301–1.121 0.106
Body mass index (1 kg/m2 increase) 1.039 0.961–1.123 0.333
Diabetes 1.189 0.587–2.404 0.631
Hypertension 1.087 0.526–2.247 0.821
Creatinine (1 μmol/L increase)  0.998 0.984–1.012 0.796
Peak CK-MB activity (1 unit increase) 1.001 1.000–1.003 0.145
Troponin AUC (1000 ng/L*24 h increase) 1.059 1.010–1.108 0.018 1.015 0.999–1.079 0.634
LVEF (1% increase) 0.943 0.914–0.973 0.000 0.936 0.902–0.971 0.000
ST elevation resolution (complete as reference):
None 1.077 0.475–2.442 0.320
Partial 0.576 0.261–1.270 0.083
Symptom duration (1 hour increase) 1.014 0.944–1.088 0.710
Angiographic and procedural 
Culprit artery (LAD vs. RCA and Cx) 1.726 0.402–7.417 0.250
Initial TIMI flow (TIMI III as reference):
0 1.747 0.597–5.114 0.750
I 3.030 1.093–8.400 0.038
II 1.146 0.359–3.655 0.530
Thrombus after reclassification  
(grade TIMI V as reference):
0 0.166 0.029–0.958 0.035
I 0.243 0.062–0.954 0.770
II 0.113 0.025–0.524 0.146
III 0.318 0.079–1.286 0.956
IV 0.484 0.150 – 1.554 0.206
Glycoprotein IIb/IIIa inhibitors use 1.031 0.541–1.965 0.926
Aspiration thrombectomy 0.837 0.405–1.730 0.230
Final TIMI flow (TIMI III as reference):
0 2.077 0.400–10.305 0.711
I 2.760 0.828–9.206 0.429
II 2.051 0.716–5.870 0.850
MBG (grade III as reference):
0 3.017 0.844–10.775 0.280
I 2.007 0.744–5.413 0.407
II 1.080 0.485–2.407 0.298
AVDE 1.295 0.540–3.106 0.561
Procedural success 0.741 0.377–1.458 0.385
cTFC (1 Frame/s increase) 1.010 0.999–1.022 0.074 1.002 0.988–1.015 0.822
QuBE (1 unit increase) 0.923 0.864–0.985 0.016 0.919 0.846–0.999 0.049
AVDE — angiographically visible distal embolization; AUC — area under the curve; CI — confidence interval; CK-MB — creatine kinase mus-
cle-brain isoenzyme; cTFC — corrected TIMI frame count; HR — hazard ratio; LAD — left anterior descending artery; Cx — circumflex artery; 
LVEF — left ventricular ejection fraction; MBG — myocardial blush grade; QuBE – quantitative blush evaluator; RCA — right coronary artery; 
TIMI — Thrombolysis in Myocardial Infarction
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scale studies, the percentage of patients with 
previous MI or having been classified in Killip 
≥ 2 class is relatively low [27], though patients 
with single vessel disease account one third of all 
STEMI patients [28]. These conditions explain the 
limited number of participants, but also enable an 
undisturbed interpretation of outcomes for this 
proof-of-concept study. To avoid doubt resulting 
from incomplete or staged revascularization in 
patients with multivessel coronary artery disease 
[29, 30]. The major difference between this study 
group and  populations from other trials is the re-
markably longer symptom duration time [27–30]. 
A considered opinion is that longer ischemic time 
translates to slightly lower QuBE score values in 
this study population in comparison to the popula-
tion from the index study [18].  
In contrast to the majority of contemporary tri-
als evaluating interventional treatment of STEMI, 
which are reporting outcomes like death, re-infarc-
tion, and target lesion revascularization, this study 
focused on HF development as a primary study 
outcome. Data was provided by the NHF. These 
data were confirmed from archive data of index 
hospitalizations and were completely consistent. 
The diagnosis of HF during index hospitalization 
was made on the basis of HF symptoms and/or 
requirements for diuretic/inotropic treatment. Ac-
cording to consistency of our source data with data 
received from NHF, it was assumed that ICD-10 
code I50.0–I50.9 will reflect the development of 
HF. Of course, such a method of outcome assess-
ment might be a source of error, but it must be 
stressed that the proof-of-concept nature of this 
study and the in-person prospective follow-up of 
patients to control for the mildest symptoms of 
HF is recommended. Based on theseassumptions, 
approximately 40% incidence of HF in 36-months 
long follow-up were reported. This is an average 
result in comparison to the 25–56.3% incidence 
reported by Araszkiewicz et al. [1] 6-months long 
follow-up and 7.8% incidence reported by Carrick 
et al. [31] in a median follow-up of 845 days. Higher 
incidence of HF development in this study in com-
parison to the Carrick study, may be attributed to 
older age, more than a twofold longer time from 
onset of symptom to reperfusion, and a twofold 
lower administration rate of GP IIb/IIIa inhibitors 
in our population. Of note, we have to be aware of 
differences in diagnostic criteria of HF. 
Of the many demographic, clinical, angio-
graphic, and procedural variables only few re-
mained significant predictors of HF development 
in the present study population. Kelly et al. [32] in 
the sub-analysis of the HORIZON-AMI trial have 
identified following determinants of new onset HF: 
previous MI, female sex, and LV systolic dysfunc-
tion, with insulin-requiring diabetes mellitus as 
a borderline correlate. 
Of note, none of the well-established angio-
graphic or procedural factors was associated with 
HF development  in that report. Only after detailed 
analysis of the impact of diabetes on myocardial 
perfusion, from the CADILLAC study, a tentative 
conclusion was formulated that the diabetic popu-
lation is more likely to have impaired myocardial 
perfusion, which may contribute to adverse out-
comes [33]. This conclusion was approached upon 
comparable use of procedural resources (GP IIb/
IIIa inhibitors, percentage of stents implanted) 
and percentage of patients with final TIMI III 
flow achieved. Comparing the stent use in our 
study with large scale randomized studies [34], 
it is substantially lower, though in comparison to 
registries [35, 36] it was at a similar level. In the 
same way, comparing the rate of final TIMI III flow 
reported herein, it is likewise with the 77% – 85% 
– 93% TIMI III flow rate reported by Vogelzang et 
al. [18] in respective subgroups, though there are 
reports on even 95% rate of TIMI III flow post-
percutaneous coronary intervention [37].
Future perspective 
The present results support the idea of another 
novel prognostic and therapeutic application of 
QuBE. It has already been shown to predict inde-
pendently all-cause and cardiovascular mortality at 
12 months [18]. It was also used by Porto et al. [38] 
to correlate microvascular obstruction with embo-
lization of coronary circulation with platelet- and 
endothelial cell-derived microparticles, while Gu 
et al. [20] have indicated that QuBE is independent 
predictor of improved functional recovery of LV. 
As QuBE software requires only one cine-loop for 
reliable, operator-independent assessment of myo-
cardial perfusion itappears to be a perfect tool for 
testing of adjunctive therapies aiming at improved 
myocardial perfusion. As its assessment can be 
repeated within a few minutes it may be suggested 
for testing drugs with vasoactive capabilities, locally 
delivered GP IIb/IIIa inhibitors, or procedures like 
ischemic post-conditioning. Improved QuBE score 
values after adjunctive treatment might be indicative 
of therapeutic efficacy and of improved outcome. 
Limitations of the study
The major limitation of this study is the ret-
rospective nature and relatively small number of 
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patients. A larger number of patients and larger 
number of complete cases would improve statistical 
significance. There is no information on other out-
comes or clinical events such as stent thrombosis, 
in-stent restenosis, re-infarction, or cardiogenic 
shock. As re-infarctions might lead to a new onset 
HF, the information on stent thrombosis, in-stent 
restenosis, target lesion revascularization would 
provide more details on the mechanisms of HF 
development in follow-up. Long inclusion period 
and the changes in the AMI treatment along this 
period may also be a confusion factor. However, 
the long recruitment period pertains to the entire 
population of 1469 STEMI patients. This peculiar 
study population of 95 patients was actually en-
rolled during a much shorter period of time: from 
2010 (1 patient) through 2013. Indeed, during 
10 years of patient enrollment remarkable changes 
in AMI treatment have occurred: from wider imple-
mentation of GP IIb/IIIa use, through introduction 
of manual thrombus aspiration, and ending up with 
100% use of drug eluting stent treatment, which 
was only  recently implemented. The interven-
tional treatment of STEMI patients, carried out 
in the middle period of the entire enrollment time 
is rather constant without  extreme variabilities.  
Conclusions 
The QuBE assessment of myocardial perfusion 
allows the prediction of HF development in the 
post-infarction period in this highly selective group 
of patients. Before wider application of QuBE for 
therapeutic and prognostic purposes a clear defini-
tion of long-term outcomes should be established. 
Moreover, more studies including broader clinical 
presentation of patients are required. 
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